A-PVP is known to produce increased heart rate, a physical effect. A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a forceful, rapid pounding felt throughout the chest, neck, and temples. This effect is among the most commonly reported physiological responses to psychoactive substances and often accompanies stimulation, anxiety, or physical exertion during intoxication.
Increased heart rate, clinically termed tachycardia when exceeding 100 beats per minute at rest, manifests as a heightened awareness of one's own cardiac rhythm. At lower intensities, users may simply notice their pulse feels slightly faster than baseline—a faint thumping sensation in the chest or a mild warmth spreading through the torso. At higher intensities, the heartbeat becomes impossible to ignore: a powerful, rapid drumming that can be felt in the throat, wrists, and behind the eyes, sometimes accompanied by visible pulsation of veins and a sensation of the heart "trying to escape" the ribcage.
The intensity of this effect follows a clear dose-dependent curve. At threshold doses of stimulants or psychedelics, heart rate may increase by only 5-15 BPM above baseline—barely perceptible without deliberately checking one's pulse. At moderate doses, increases of 20-40 BPM become noticeable during both activity and rest, often accompanied by a subtle chest tightness. At high doses or during combinations, heart rate can spike to 140-180+ BPM, producing significant discomfort, breathlessness, and anxiety that may trigger panic responses that further compound the tachycardia.
Several distinct subtypes exist. Stimulant-induced tachycardia tends to feel "electric" and buzzing, as if the heart is running at high RPM but smoothly. Psychedelic tachycardia is often intermittent and closely tied to emotional state—surges of awe or anxiety produce momentary spikes. Cannabinoid-induced increases feel more diffuse and are frequently accompanied by postural hypotension. Dissociative tachycardia is often less consciously noticed due to the analgesic and detaching properties of these substances, making it particularly insidious.
Pharmacologically, increased heart rate results from several mechanisms: direct sympathomimetic activation (as with amphetamines and cocaine, which increase catecholamine release), vagal nerve suppression (as with anticholinergic compounds), peripheral vasodilation triggering baroreceptor-mediated compensatory tachycardia (as with cannabis and some psychedelics), or direct agonism at cardiac beta-adrenergic receptors. Serotonergic compounds can also produce tachycardia via 5-HT2A and 5-HT2B receptor activation.
This effect is most prominently associated with stimulants (amphetamines, cocaine, MDMA, caffeine), but it is also common with psychedelics (LSD, psilocybin, mescaline), cannabinoids (THC), dissociatives (PCP, ketamine at higher doses), and empathogens. Essentially, any substance that activates the sympathetic nervous system or suppresses parasympathetic tone can produce it.
From a harm reduction perspective, increased heart rate becomes dangerous when sustained at very high levels, in individuals with pre-existing cardiac conditions, or when combined with other cardiotoxic substances. The combination of stimulants with MAOIs or other stimulants poses particular risk for hypertensive crisis. Users experiencing tachycardia should avoid further stimulant intake, remain hydrated, practice slow breathing techniques, and seek medical attention if heart rate exceeds 150 BPM at rest or is accompanied by chest pain, irregular rhythm, or difficulty breathing.
Increased heart rate can manifest at varying intensities depending on the dose of A-PVP and individual sensitivity. The following levels describe the typical progression of this effect.
A subtle awareness of one's heartbeat, only noticeable when paying attention. Heart rate increased by 5-15 BPM above baseline.
Heart rate is clearly elevated and noticeable during rest. Mild warmth in the chest. Increase of 15-30 BPM.
A pronounced, forceful heartbeat felt in the chest, neck, and wrists. Accompanied by mild breathlessness. Increase of 30-50 BPM.
Rapid, pounding heartbeat that dominates body awareness. Visible pulsation in veins. Accompanied by anxiety and chest tightness. 50-70+ BPM above baseline.
An extremely rapid, forceful heartbeat exceeding 150 BPM at rest. May feel chaotic or irregular. Accompanied by significant distress, breathlessness, and potential medical danger.
A-PVP acts as a potent and selective norepinephrine-dopamine reuptake inhibitor (NDRI). It binds to the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking the reuptake of dopamine and norepinephrine from the synapse into presynaptic neurons. The result is sustained elevation of synaptic dopamine and norepinephrine concentrations, producing the stimulant and euphoric effects.
A-PVP is notably more potent as an NDRI than classical stimulants such as cocaine and amphetamine. Comparative pharmacological studies have shown A-PVP to be a more potent inhibitor of DAT and NET than cocaine at equivalent concentrations, which in part explains why the subjective potency and addictive potential exceed those of cocaine in user accounts.
A critical pharmacological distinction: A-PVP is NOT a transporter substrate. It does not cause active neurotransmitter release in the manner of amphetamine or methcathinone. This means A-PVP cannot deplete vesicular neurotransmitter stores and does not produce the characteristic "amphetamine-like" release pattern. However, this does not confer a safety advantage — the sustained high-affinity reuptake blockade produces its own pattern of intense dopaminergic signaling.
A-PVP has minimal activity at the serotonin transporter (SERT). This pharmacological selectivity — potent DAT/NET inhibition with negligible SERT activity — explains the purely stimulant/euphoric character of the experience and the absence of entactogenic qualities. It also means there is no serotonergic "ceiling" on the dopaminergic stimulation, which may contribute to psychosis risk.
A-PVP is active at milligram doses. When vaporized, onset is within seconds; insufflated onset is 3–5 minutes. Peak effects are brief — 30–60 minutes — followed by a rapid descent that drives redosing. The total duration per administration is typically 1–3 hours, though residual stimulation and dysphoria extend considerably beyond peak effects.
Tolerance develops rapidly, often within a single extended use session, creating pressure to escalate dose and frequency.
A-PVP can be administered via insufflated, oral, smoked. The route of administration can influence both the onset and intensity of increased heart rate.
The intensity of increased heart rate depends heavily on the dose of A-PVP. Effects like increased heart rate are typically reported at common to strong doses. Below is the full dosage chart for A-PVP.
Warning
Sustained heart rates above 150 BPM can strain the cardiovascular system and may trigger arrhythmias in susceptible individuals. This effect is particularly dangerous when combining stimulants, in people with pre-existing heart conditions, or with substances that prolong the QT interval. Seek medical attention for chest pain, irregular rhythm, or sustained extreme tachycardia.
Yes. Increased heart rate is a documented physical effect of A-PVP. A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a forceful, rapid pounding felt throughout the chest, neck, and temples. This effect is among the most commonly reported physiological responses to psychoactive substances and often accompanies stimulation, anxiety, or physical exertion during intoxication.
Effects like increased heart rate are typically reported at common doses and above. A common insufflated dose of A-PVP is 5–15 mg.
Other substances documented to produce increased heart rate include Amphetamine, Cocaine, MDMA, Cannabis, Caffeine, and 35 more.